Very low affinity insulin analogue

Human insulin (NNC0121-0308) is available as a reference compound to NNC0121-0038. Please indicate (with a check mark at ‘Please add the reference compound if available) during your compound request if you would like to have human insulin (NNC0121-0308) included in your shipment.

Peptides and proteins tend to adhere to glass and plastic surfaces. This may at low concentration impact the actual amount in solution. To minimize this unspecific adherence, adding detergents or inert proteins like e.g., ovalbumin or other serum albumins to the solution can minimize this phenomenon. In case albumins are added to peptide/protein solutions, ensure that the albumins are free of any proteases. Recommended procedure for in vitro studies: dissolve the entire content of the vial by adding 4 mL 30 mM HEPES buffer pH 8. Gently rotate the vial until all content is dissolved. Avoid harsh shaking or stirring of the solution. Keep the stock solution at 4C overnight and make the desired number of aliquots (use low protein binding vials) of the stocks. Snap freeze the aliquots in liquid nitrogen and store them at minus 20C. When thawed, the stock solution should be stable for up to three weeks at 4C. Recommended procedure for in vivo studies: NNC0121-0038 (and the human insulin reference) can be dosed in vivo in a zinc-free and phenol/m-cresol-free formulation vehicle. This vehicle may contain 10mM sodium phosphate, 140mM sodium chloride, pH 7.4. If concentrations of the intended dosing formulations are very low (low uM to sub nM concentrations), adsorption to vials may affect the measurable concentration. In this case, consider adding 0.007% polysorbate 20. If insulin oligomeric/multimeric properties are of interest, zinc and phenol/m-cresol can be added. Zinc is typically added as zinc acetate between 0 and 6 moles/mole of insulin analogue. The resulting tonicity should be recalculated. Formulations should be used fresh but can be stored for up to one week refrigerated.